Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Fallopian Tube Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Peritoneal Neoplasms 1 Neoplasms 1 Melanoma 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Limited Stage Small Cell Lung Cancer 1 Hepatic Encephalopathy 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 166 Nivolumab 111 Ipilimumab 93 Dacarbazine 44 trametinib 36 dabrafenib 34 Vemurafenib 33 binimetinib 23 atezolizumab 23 Temozolomide 21 cemiplimab 18 Paclitaxel 18 encorafenib 17 spartalizumab 16 cobimetinib 15 Carboplatin 14 talimogene laherparepvec 13 Cisplatin 13 Cyclophosphamide 12 lenvatinib 10 Pemetrexed 10 Gemcitabine 10 Docetaxel 10 durvalumab 9 Drug Therapy 9 Bevacizumab 9 tremelimumab 8 Injections 8 Albumin-Bound Paclitaxel 8 130-nm albumin-bound paclitaxel 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma × Glucose × Clear all

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡